Markers for microvascular invasion in hepatocellular carcinoma: Where do we stand?

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Gouw, Annette S H ^a   Balabaud, Charles ^b   Kusano, Hironori ^a   Todo, Satoru ^c   Ichida, Takafumi ^d   Kojiro, Masamichi ^e  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANGIOPOIETIN 2; DECARBOXYPROTHROMBIN;

CANCER EPIDEMIOLOGY; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE MARKER; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MICROVASCULARIZATION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME; ULTRASOUND;

CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; HEALTH STATUS INDICATORS; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MICROVESSELS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80053246324     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22368     Document Type: Note

References (55)

1. Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 2002; 6: 224-232. (Pubitemid 40433575)
2. Shah SA, Tan JC, McGilvray ID, Cattral MS, Levy GA, Greig PD, Grant DR,. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007; 11: 464-471.
3. Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG, et al. Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 2007; 13: 543-551. (Pubitemid 46605857)
4. Löhe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Löhrs U, et al. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007; 21: 696-701. (Pubitemid 350056135)
5. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080-1086. (Pubitemid 32378206)
6. Bhattacharjya S, Bhattacharjya T, Quaglia A, Dhillon AP, Burroughs AK, Patch DW, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: an analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg 2004; 21: 152-159. (Pubitemid 38812955)
7. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, Aishima S, Maehara Y,. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007; 95: 235-240.
8. Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 1086-1092. (Pubitemid 41341758)
9. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 3rd ed. Tokyo, Japan: Kanehara & Co., Ltd., 2010.
10. Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohtomo K, Makuuchi M,. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000; 33: 975-979.
11. Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375-1382.
12. Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M,. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003; 26: 142-147. (Pubitemid 36927185)
13. Kaibori M, Ishizaki M, Matsui K, Kwon AH,. Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010; 102: 462-468.
14. Shirabe K, Aishima S, Taketomi A, Soejima Y, Uchiyama H, Kayashima H, et al. Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation. Br J Surg 2011; 98: 261-267.
15. Roskams T, Kojiro M,. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis 2010; 30: 17-25.
16. Cucchetti A, Vivarelli M, Piscaglia F, Nardo B, Montalti R, Grazi GL, et al. Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005; 43: 310-316. (Pubitemid 40956885)
17. Brubaker WD, Zaretsky J, Chang MS, Halazun KJ, Lim E, Siegel A, et al. Volumetric tumor growth rate as a predictor of HCC recurrence after liver transplantation [abstract]. Hepatology 2010; 52 (suppl 1): 1152A.
18. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009; 9: 592-600.
19. Decaens T, Itti E, Laurent A, Luciani A, Van Nhieu JT, Auriault ML, et al. Role of FDG PET in patients scheduled for liver transplantation (LT) for hepatocellular carcinoma (HCC) [abstract]. Hepatology 2010; 52 (suppl 1): 662A.
20. Robinson E, Chandarana H, Droxhinin L, Hajdu C, Xu R, Teperman L, Taouli B,. MRI features of HCC do not predict microvascular invasion in liver transplant for hepatocellular carcinoma [abstract]. Liver Transpl 2009; 15 (suppl 7): S111.
21. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I, Kanematsu T,. Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 2010; 34: 1034-1038.
22. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-569. (Pubitemid 32105702)
23. Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S,. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009; 9: 2362-2371.
24. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers (AFP, AFP-L3, and DCP) in patients with chronic hepatitis C (CHC) and advanced fibrosis with and without HCC [abstract]. Hepatology 2010; 52 (suppl 1): 328A.
25. Cescon M, Ravaioli M, Grazi GL, Ercolani G, Cucchetti A, Bertuzzo V, et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010; 2010: 904152.
26. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant 2010; 10: 129-137.
27. Louha M, Poussin K, Ganne N, Zylberberg H, Nalpas B, Nicolet J, et al. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer. Hepatology 1997; 26: 998-1005. (Pubitemid 27413670)
28. Vona G, Estepa L, Béroud C, Damotte D, Capron F, Nalpas B, et al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 2004; 39: 792-797. (Pubitemid 38337659)
29. Paterlini-Brechot P, Benali NL,. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007; 253: 180-204. (Pubitemid 47017533)
30. Diaz-Sanchez A, Matilla AM, Nañez A., Lorente R, Fernandez A, Rincon D, et al. Serum angiopoietin-2 level is a predictor of tumour invasiveness in patients with hepatocellular carcinoma [abstract]. Hepatology 2010; 52 (suppl 1): 1180A.
31. Ding ZB, Shi YH, Zhou J, Shi GM, Ke AW, Qiu SJ, et al. Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. Cancer 2009; 115: 4753-4765.
32. Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, et al. Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery 2010; 147: 405-414.
33. Cucchetti A, Piscaglia F, Grigioni AD, Ravaioli M, Cescon M, Zanello M, et al. Preoperative prediction of hepatocellular carcinoma tumour grade and micro-vascular invasion by means of artificial neural network: a pilot study. J Hepatol 2010; 52: 880-888.
34. Siegel AB, Wang S, Jacobson JS, Hershman DL, Lim EA, Yu J, et al. Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest 2010; 28: 1063-1069.
35. Roayaie S, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009; 137: 850-855.
36. Cucchetti A, Piscaglia F, Caturelli E, Benvegna L, Vivarelli M, Ercolani G, et al. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-422.
37. Choi SH, Lee HH, Lee DS, Choi JH, Heo JS, Lee KW, et al. Clinicopathological features of incidental hepatocellular carcinoma in liver transplantation. Transplant Proc 2004; 36: 2293-2294. (Pubitemid 39550819)
38. Dudek K, Kornasiewicz O, Remiszewski P, KobryÅ K, Ziarkiewicz-Wrõblewska B, Gõrnicka B, et al. Impact of tumor characteristic on the outcome of liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2009; 41: 3135-3137.
39. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al.; for Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory study. Lancet Oncol 2009; 10: 35-43.
40. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP,. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8: 765-774. (Pubitemid 35012284)
41. Coelho GR, Vasconcelos KF, Vasconcelos JB, Barros MA, Costa PE, Borges GC, et al. Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the northeast of Brazil. Transplant Proc 2009; 41: 1740-1742.
42. Park YK, Kim BW, Wang HJ, Kim MW,. Hepatic resection for hepatocellular carcinoma meeting Milan criteria in Child-Turcotte-Pugh class A patients with cirrhosis. Transplant Proc 2009; 41: 1691-1697.
43. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862.
44. Silva M, Moya A, Berenguer M, Sanjuan F, Lõpez-Andujar R, Pareja E, et al. Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transpl 2008; 14: 1449-1460.
45. Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU,. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007; 25: 329-333. (Pubitemid 350014961)
46. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J,. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010; 36: 275-280.
47. Lai Q, Merli M, Ginanni Corradini S, Mennini G, Gentili F, Molinaro A, et al. Predictive factors of recurrence of hepatocellular carcinoma after liver transplantation: a multivariate analysis. Transplant Proc 2009; 41: 1306-1309.
48. D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009; 15: 1278-1287.
49. Lee KW, Park JW, Joh JW, Kim SJ, Choi SH, Heo JS, et al. Can we expand the Milan criteria for hepatocellular carcinoma in living donor liver transplantation? Transplant Proc 2004; 36: 2289-2290. (Pubitemid 39550817)
50. Nguyen JH, Harnois DM, Rosser B, Pungpapong S, Satyanarayana R, Willingham DL, et al. Liver transplantation for hepatocellular carcinoma within and beyond Milan criteria: microvascular invasion holds the key [abstract]. Hepatology 2010; 52 (suppl 1): 854A.
51. Ferrer J, Sposito C, Fuster J, Forner A, Bruix J, Llovet JM, et al. Should indications for liver transplantation be expanded in patients with hepatocellular carcinoma? Lessons learned from a retrospective analysis of tumor characteristics beyond the Milan criteria [abstract]. Hepatology 2010; 52 (suppl 1): 1141A.
52. El-Gazzaz G, Aucejo FN, Narayanan Menon KV, Miller CM, Quintini C, Eghtesad B, et al. Outcome of pre-transplant locoregional therapy to downstage hepatocellular carcinoma [abstract]. Hepatology 2010; 52 (suppl 1): 855A.
53. Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteriaâselection parameter for liver transplantation. Radiology 2010; 255: 289-300.
54. Plessier A, Codes L, Consigny Y, Sommacale D, Dondero F, Cortes A, et al. Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma. Liver Transpl 2004; 10 (suppl 1): S86-S90. (Pubitemid 38240107)
55. Fan J, Yang GS, Fu ZR, Peng ZH, Xia Q, Peng CH, et al. Liver transplantation outcomes in 1,078 hepatocellular carcinoma patients: a multi-center experience in Shanghai, China. J Cancer Res Clin Oncol 2009; 135: 1403-1412.